Avantax Advisory Services’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Avantax Advisory Services’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,329	Closed	-$254K	–	1593
2023 Q1	$254K	Sell	2,329 -29	-1%	-$3.21K	﹤0.01%	1245
2022 Q4	$268K	Buy	+2,358	New	+$196K	﹤0.01%	1163
2021 Q2	–	Sell	-4,763	Closed	-$438K	–	1174
2021 Q1	$438K	Buy	+4,763	New	+$402K	0.01%	666
2020 Q4	–	Sell	-10,603	Closed	-$824K	–	1414
2020 Q3	$824K	Buy	+10,603	New	+$730K	0.01%	598

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Avantax Advisory Services's HZNP Position: Q2 2023 in Review

Avantax Advisory Services sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 2,329 shares — an estimated $254K sold.

Avantax Advisory Services first reported a position in HZNP in Q3 2020 and held it in 4 quarters. The position peaked at $824K in Q3 2020. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Avantax Advisory Services reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Avantax Advisory Services sold 2,329 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $254K.
Avantax Advisory Services first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 4 quarters.
Avantax Advisory Services's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $824K in Q3 2020.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Avantax Advisory Services's 13F filing for Q2 2023, filed 11 Aug 2023.